AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Abbott CEO Robert Ford speaks on earnings call
ByAinvest
Thursday, Jul 17, 2025 9:21 am ET1min read
Abbott CEO Robert Ford speaks on earnings call
Abbott Laboratories (NYSE: ABT) reported robust financial performance for the second quarter of 2025, with sales growth of 7.4 percent and organic sales growth of 6.9 percent, excluding COVID-19 testing-related sales [1]. The company's adjusted diluted EPS was $1.26, reflecting double-digit growth compared to the prior year. CEO Robert B. Ford expressed optimism about the company's momentum, projecting full-year 2025 organic sales growth of 7.5 percent to 8.0 percent, excluding COVID-19 testing-related sales, and adjusted diluted EPS of $5.10 to $5.20 [1].The second quarter saw Abbott's sales increase 14.6 percent in the U.S. and 12.4 percent internationally, with organic growth rates of 14.6 percent and 12.2 percent, respectively [1]. The company's gross margin improved to 52.7 percent of sales, and the operating margin increased to 18.4 percent [1]. Abbott's medical devices segment experienced strong growth, with sales up 12.4 percent and organic sales growth of 12.2 percent [1].
In the second quarter, Abbott reported significant advancements in its product pipeline. The company completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which aims to evaluate the TactiFlex™ Duo Pulsed Field Ablation (PFA) System for treating heart rhythm disorders such as atrial fibrillation (AFib) [1]. Abbott also announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) clinical feasibility study and received FDA approval for its Tendyne™ transcatheter mitral valve replacement (TMVR) system [1].
Looking ahead, Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in Georgia, set to be completed by 2028 [1]. The company's CEO expressed confidence in the company's ability to sustain growth and momentum, stating, "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline. We see this momentum carrying into 2026" [1].
References:
[1] https://abbott.mediaroom.com/2025-07-17-Abbott-Reports-Second-Quarter-2025-Results
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet